WBC100 QD

Zhejiang University · Phase 1 active Small molecule Quality 0/100

At a glance

Generic name	WBC100 QD
Sponsor	Zhejiang University
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Clinical Trial of WBC100 on Advanced Solid Tumor (PHASE1)
Clinical Trial of WBC100 Capsule in Relapsed/Refractory Acute Myeloid Leukemia (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

WBC100 QD CI brief — competitive landscape report
WBC100 QD updates RSS · CI watch RSS
Zhejiang University portfolio CI